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Role of the 11b-hydroxysteroid dehydrogenase type 2 in blood for the enzyme (Fig. 1) [1, 2]. Cortisol and aldosterone
pressure regulation. The renal 11b-hydroxysteroid dehydroge- have the same intrinsic affinity for the mineralocorticoid
nase type 2 (11bHSD2) enzyme inactivates 11-hydroxy steroids receptor (MR) [3]. Both corticosteroids are secretedin the kidney, thus protecting the nonselective mineralocorti-
from the adrenal cortex, cortisol in large amounts (10 tocoid receptor (MR) from occupation by glucocorticoids. The
20 mg/day), while aldosterone in much smaller amountsgene is highly expressed in all sodium-transporting epithelia,
but also in human placenta, pancreas, and thyroid. Mutations (0.10 to 0.15 mg/day). Thus, it has been proposed that the
in the HSD11B2 gene cause a rare monogenic juvenile hyper- 11bHSD enzyme functions as a protective mechanism,
tensive syndrome called apparent mineralocorticoid excess preventing glucocorticoid binding to both the MR in(AME). In AME, compromised 11bHSD2 enzyme activity re-
aldosterone target tissues such as the cortical collectingsults in overstimulation of the MR by cortisol, causing sodium
tubules of the kidney [1, 4] and to the glucocorticoidretention, hypokalemia, and salt-dependent hypertension. Re-
cent evidence suggests a role of the 11bHSD2 in essential receptor (GR) [5]. 11bHSD activity is not, however, lim-
hypertension. We found hypertension with no other character- ited to aldosterone-responsive tissues, but is widespread
istic signs of AME in the heterozygous father of a child with in terms of distribution [6–8]. The recent discovery ofAME and in a girl with a homozygous gene mutation resulting
two kinetically distinct forms of 11bHSD (11bHSD1 andin a mild deficiency of 11bHSD2. Moreover, some studies in
11bHSD2), differentiated in addition by cofactor speci-patients with essential hypertension showed a prolonged half-
life of cortisol and an increased ratio of urinary cortisol to ficity, has resolved this apparent paradox [6, 8–10]. The
cortisone metabolites, suggesting a deficient 11bHSD2 activity. two isoenzymes share only 14% identity and have differ-
These abnormalities may be genetically determined. A genetic ent physiological roles, regulation, and tissue distribu-association of a microsatellite flanking the HSD11B2 gene and
tion. 11bHSD1 activity and expression are found in mosthypertension in black patients with end-stage renal disease
tissues; its Km for cortisol is more than one order ofhas been reported. We recently analyzed a CA-repeat allele
polymorphism in unselected patients with essential hyperten- magnitude higher than 11bHSD2; it is nicotinamide ade-
sion, but did not find any correlation between this marker and nine dinucleotide phosphate (NADP) preferring and has
blood pressure. However, we did find an association between
been shown to have predominantly reductase activitythis polymorphic CA microsatellite marker and salt sensitivity.
[6–8]. In contrast, 11bHSD2 is expressed mainly in so-Moreover, the activity of the 11bHSD2, as shown by elevated
mean ratios of urinary cortisol to cortisone metabolites, was dium-transporting epithelia and the placenta [9–11]; it
decreased in salt-sensitive compared with salt-resistant sub- has a high affinity for cortisol, is NAD requiring, and
jects. These findings indicate that variants of the HSD11B2 appears to show only dehydrogenase activity with natu-
gene contribute to the enhanced blood pressure response to
rally occurring glucocorticoids, although reductase activ-salt in humans.
ity predominates with some synthetic steroids [9, 10, 12].
Importantly, immunohistochemical studies have local-
ized 11bHSD2 to the distal tubule [13]. Thus, the roleThe 11b-hydroxysteroid dehydrogenase (11bHSD) is
of the 11bHSD2 enzyme is to confer aldosterone selectiv-a microsomal enzyme responsible for the interconver-
ity on the MR, whereas 11bHSD1 reactivates 11-ketosion of active 11-hydroxy-glucocorticoids to their recep-
glucocorticoid metabolites.tor inactive 11-keto-metabolites, while the hemiacetal
Because a normal activity of 11bHSD2 is essentialgroup of aldosterone renders this steroid a poor substrate
for prevention of mineralocorticoid activity of cortisol,
absent or decreased 11bHSD2 activity results in cortisol-
mediated mineralocorticoid hypertension. DecreasedKey words: hypertension, genetics, 11bHSD2, mineralocorticoid re-
ceptor, apparent mineralocorticoid excess, renal sodium retention. 11bHSD2 activity has been demonstrated to be the
pathogenetic mechanism of increased blood pressure inÓ 2000 by the International Society of Nephrology
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Fig. 1. The 11b-hydroxysteroid dehydroge-
nase (11bHSD) is the key enzyme protecting
the mineralocorticoid receptor (MR) from oc-
cupation by cortisol. Two enzymes are in-
volved in the process of interconversion of
cortisol and cortisone. 11bHSD1 is a low-
affinity oxo-reductase, whereas 11bHSD2 is a
high-affinity oxidase. Cortisol and aldosterone
have the same intrinsic affinity for the MR.
While in humans cortisol is the prime sub-
strate for 11bHSD2, the hemiacetal conforma-
tion of the 11-hydroxyl group with the 18-
aldehyde group of aldosterone renders this
steroid a poor substrate for the enzyme.
the syndrome of apparent mineralocorticoid excess lateral sodium/potassium ATPase are increased upon
stimulation by aldosterone (Fig. 2) [27, 28]. Moreover,(AME) [14–16]. In this autosomal recessive disorder,
diminished or absent 11bHSD2 activity is caused by mu- the nongenomic effects of aldosterone, such as the meth-
ylation of the sodium channel, may contribute to thetations in the HSD11B2 gene coding for 11bHSD2 en-
zyme [17–22]. Licorice-induced hypertension results increased aldosterone-mediated sodium reabsorption
[29, 30].from glycyrrhetinic acid, the active constituent of lico-
The amino acid sequences of the MR and GR haverice, inhibiting 11bHSD2 and resulting in overstimula-
a high degree of sequence homology. The identity istion of the MR by cortisol [23]. There is also growing
approximately 94% at the center of the molecule in theevidence for decreased 11bHSD2 activity in essential
DNA-binding domain and 55 to 60% in the C-terminalhypertension. Although MR in the central nervous sys-
ligand-binding domain.tem has been implicated in the pathogenesis of mineralo-
With the cloning and expression of the MR [3], itcorticoid hypertension [24, 25], a pathophysiological role
was observed that aldosterone and cortisol had similarfor 11bHSD has not yet been described. In fact, a correc-
binding affinities for the MR in vitro. Circulating levelstion of hypertension by kidney transplantation in a pa-
of cortisol in humans and corticosterone in rodents aretient with AME [26] favorably argues against a role for
two to three order of magnitudes higher than aldosteroneMR in the central nervous system in the pathogenesis
levels. However, in vivo, only aldosterone acts as a physio-of hypertension related to 11bHSD2 deficiency.
logic agonist of the MR. This apparent paradox was solved
with the discovery of the microsomal enzyme 11bHSD
ALDOSTERONE, CORTICOSTEROID [1, 4]. In mineralocorticoid target tissues, the type 2
RECEPTORS, AND 11b-HYDROXYSTEROID isoenzyme converts the biologically active 11-hydroxy-
DEHYDROGENASE steroid to their inactive 11-keto-steroid forms, thus con-
The most well-defined physiological action of aldoste- ferring ligand specificity on the MR. The hemiacetal
rone is the regulation of electrolyte and volume balance conformation of the 11-hydroxyl group with the 18-alde-
through its renal action on the distal tubule and cortical hyde group of aldosterone renders this molecule a poor
collecting duct. Stimulation of these cells with aldoste- substrate for 11bHSD. Of the two cloned 11bHSD iso-
rone results in sodium reabsorption and potassium excre- forms, only type 2 (11bHSD2) acts to protect the MR.
Transgenic mice deficient for 11bHSD1 do not showtion. Most effects of aldosterone are mediated by a spe-
cific nuclear receptor, the MR. Aldosterone binding to signs of mineralocorticoid excess [31], while 11bHSD2
knockout mice have hypoaldostronemic mineralocorti-its cognate receptor enhances the transcription of aldo-
sterone-inducible proteins. The synthesis of the subunits coid hypertension [32], as do their human counterparts
with genetic 11bHSD2 deficiency.of the (apical) epithelial sodium channel and of the baso-
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Fig. 2. Mineralocorticoid action in renal cells
of the distal tubule and cortical collecting duct.
When aldosterone enters the cell, it binds to
the mineralocorticoid receptor (MR), and
thereafter the ligand-receptor complex is
translocated into the nucleus. Binding to min-
eralocorticoid response elements (MRE) in-
creases the transcription of genes encoding
specific aldosterone-inducible proteins, such
as the subunits of the apical epithelial sodium
channel (ENaC) and of the basolateral so-
dium-potassium (Na/K) ATPase. In turn, this
stimulates sodium (Na1) reabsorption and po-
tassium (K1) excretion. Cortisol circulates at
100- to 1000-fold higher levels than aldoste-
rone and would therefore occupy the MR be-
cause it has a similar affinity for the receptor
as aldosterone. However, the MR is protected
from occupation by glucocorticoids because
the 11bHSD2 oxidizes cortisol into its recep-
tor inactive form cortisone. In apparent miner-
alocorticoid excess, the absent 11bHSD2 ac-
tivity leads to an unrestricted activation of the
MR by cortisol and thus to increased sodium
retention and hypokalemic hypertension with
low renin and aldosterone levels.
SYNDROME OF APPARENT fective in some cases. Mutations in the HSD11B2 gene
MINERALOCORTICOID EXCESS were subsequently demonstrated to cause the 11bHSD2
deficiency [17–22]. Because plasma cortisol levels are inThe syndrome of AME causing a severe form of juve-
the nanomolar range while aldosterone levels are in thenile, low-renin, low-aldosterone hypertension was first
picomolar range, a deficient 11bHSD2 enzyme activitydescribed in 1974 by Werder et al [14] and was later
results in cortisol saturation of MR in AME patients.characterized biochemically by New et al [15, 16]. To
This excess stimulation of MR results in hypokalemia,date, approximately 50 distinct cases have been reported
sodium retention, and volume expansion, with suppres-worldwide (abstract; Odermatt et al, J Am Soc Nephrol
sion of plasma renin and aldosterone secretion. Thus, the10:352A, 1999) [17–22, 33–38]. The typical clinical signs
hallmark of the disease is the state of mineralocorticoidand symptoms of AME include severe salt-dependent hy-
excess in the absence of aldosterone.pertension, hypokalemia, hypoaldosteronemia, and sup-
Cloning of the gene encoding for the human 11bHSD2pressed plasma renin activity but also low birth weight,
has allowed the identification of mutations in AME pa-failure to thrive, polyuria and polydipsia, and nephrocal-
tients [10]. The HSD11B2 gene is composed of five exonscinosis. The disease is inherited as an autosomal recessive
and is located on chromosome 16q22 [39]. We and otherstrait. The pathogenesis of AME was found to be a defec-
have identified mutations in the HSD11B2 gene, to datetive peripheral conversion of cortisol to cortisone re-
revealing 20 different genotypes (Table 1) (abstract; Od-flecting a deficiency of 11bHSD2 enzyme, resulting in
ermatt et al, J Am Soc Nephrol 10:352A, 1999) [17–22,excess cortisol binding to the MR [15, 16]. The profile
33–38]. All known mutations have been found in exonsof urinary steroids in patients with AME is characterized
3, 4, or 5 of the HSD11B2 gene, with the exception ofby a relative increase in the excretion of A-ring–reduced
the L114,D6nt mutant (abstract; Odermatt et al, J Ammetabolites of cortisol [tetrahydrocortisol (THF) 1
Soc Nephrol 10:352A, 1999). Most of the patients de-5aTHF], while levels of A-ring–reduced cortisone me-
scribed had characteristic signs of severe 11bHSD2 defi-tabolites [tetrahydrocortisone (THE)] are very low or
ciency. Birth weights were significantly lower than theirabsent [16]. Signs and symptoms of the syndrome can
unaffected sibs, and the patients were short, under-be partially or fully reversed by treatment with the MR-
weight, and hypertensive for age. The 11bHSD2 activity,antagonist spironolactone, although very high doses
as assessed by the urinary excretion ratio of cortisolmight be required to compete the effects of cortisol on
(THF 1 5aTHF) to cortisone (THE) metabolites, wasthe MR. Some patients do respond better with triamter-
ene or amiloride, and dexamethasone has also been ef- characteristically abnormal, with ratios of 6 to 50,
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Table 1. Mutations in the 11b-hydroxysteroid dehydrogenase type an increased ability to conserve sodium under conditions
2 gene in patients with AME
of extreme salt deprivation.
Mutation Percent activity or Km Reference Depending on the degree of loss of enzyme activity,
Homozygotes 11bHSD2 mutations can cause a spectrum of hyperten-
Exon 2 sion ranging from a severe, life-threatening childhood
aL114,D6nt Km 5 55 nmol/L, [39] disease to a milder form diagnosed only in adults. ThisVmax 5 2% wt
Exon 3 view is also supported by the recent clarification of the
R186C 0 [20, 21] molecular basis of the so-called “AME type II” [38, 40].
R208C 1.5 [17, 36]
In “AME type II,” the urinary ratio of (THF 1 5aTHF)/R208H 0 [34]
R213C 3.6 [17] THE is only slightly elevated, while the main abnormal-
ity in cortisol metabolism is a defect in cortisol A-ringIntron 3
C ! T 0b [17] reduction [40]. Thus, a defect other than 11bHSD2 defi-
Exon 4 ciency was thought to cause this disorder. However, pa-
P227L Km 5 284 nmol/L [37] tients with AME type II have a prolonged plasma half-Y232,D9nt 0 [17]
L250P,L251S 0 [17, 20, 21] life for [11a-3H]-cortisol like in classic AME [40]. In fact,
molecular analysis of a large pedigree with AME typeExon 5
R279C Km 5 55 nmol/L, [38] II from Sardinia revealed a C945T mutation resulting in
Vmax 5 60% wt the substitution of a cysteine for an arginine at codonN286,D1nt 0b [36]
279 (R279C mutation) in 11bHSD2. The in vitro expres-G305D11nt 0 [17]
A328V 0 [35] sion of the mutant enzyme showed an identical affinity
R337C Km 5 1010 nmol/L [18, 19, 22] for cortisol as the wild-type enzyme, while the maximumR337H,D3nt 0 [17, 20]
velocity was reduced by approximately 35% [38]. Inhibi-E356,D1nt 0 [20, 21]
R374stop 0 [54] tion of 11bHSD2 activity by excessive ingestion of glycyr-
Compound heterozygotes rhetinic acid results in an acquired form of AME, which
R208H and 0 [34] is associated with an increase in the urinary ratio (THF 1
R337H,D3nt
5aTHF)/THE of similar degree to that observed inY232,D9nt and 0 [17]
G305,D11nt “AME type II” [23].
D244N and L250R 0b [36]
Mutations not characterized to date are: L179R, S180F, A327V.
a For each mutation, the letter indicates the amino acid and the number the 11bHSD2 ACTIVITY IN
codon ESSENTIAL HYPERTENSIONb Presumed to be inactive on the basis of protein structure
In the general population, hypertension has a preva-
lence of 20 to 30%, depending on the definition. The ill-
defined concept of “essential” hypertension is used to
whereas the normal ratio was 1.0. In vitro mutagenesis label the approximately 95% of cases of hypertension
showed that most of the mutations result in the expres- in which no underlying cause for the increased blood
sion of a 11bHSD2 protein, with completely abolished pressure can be found. Over the past few years, several
or severely impaired enzymatic activity [17–19, 21, 22, forms of so-called monogenic hypertension have been
34–36]. Nevertheless, some patients with homozygous identified. All of these forms are part of the extended
mutations from different families may have varying de- renin-angiotensin system and affect the renal sodium
grees of severity in clinical and biochemical features (ab- transport. These studies have advanced our knowledge
stract; Odermatt et al, J Am Soc Nephrol 10:352A, 1999) of the genetic basis of cardiovascular disease. Several
[37, 38]. For instance, we reported on a form of low- ongoing studies are trying to clarify the role of these
renin hypertension in which a gene mutation produces genes and are assessing the prevalence of mutations in
a mild deficiency in the 11bHSD2 enzyme, but without these gene products in patients currently labeled as hav-
other phenotypic features characteristic of AME [37]. ing “essential” hypertension.
Based on clinical observation and in vitro cotransfection Patients with essential hypertension do not have overt
experiments, it seems likely that 11bHSD2 activity also signs of mineralocorticoid excess; however, more subtle
might be mildly impaired in the heterozygote state [22], changes such as a positive correlation between blood
thus predisposing or promoting isolated late-onset hy- pressure and serum sodium levels or a negative correla-
pertension. In fact, recently, the heterozygous father of tion with potassium levels suggest a corticosteroid influ-
a child with AME in a Brazilian kindred was found to ence [41]. Variations in 11bHSD2 activity can be as-
have hypertension with no other characteristic signs of sessed using the ratio of urinary cortisol to cortisone
AME [35]. It has been suggested that heterozygosity metabolites or plasma cortisol half-life. Recent studies
have shown that in some patients with essential hyper-might have the possible selective advantage of conferring
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tension, the half-life of cortisol is significantly prolonged,
the excretion of urinary cortisol metabolites is increased,
and the vasoconstrictor response to glucocorticoids is
enhanced [42–44]. In the “4 corner study,” an impaired
conversion of cortisol to inactive metabolites has also
been reported in young men with higher blood pressure
whose parents also had high blood pressure [45]. An-
other study found a positive association between urinary
free cortisol and salt-resistant hypertension [46]. Other
authors, however, did not confirm these observations
[47, 48]. There are several possible explanations for this
discrepancy, notably the differences in the ethnic groups,
age, and selection criteria. Nevertheless, these studies
suggest that the 11bHSD2 enzyme may play a role at
least in a subset of patients with essential hypertension.
It is noteworthy that all monogenic causes of hyperten-
sion described so far are known to be involved in sodium
homeostasis at one point or another. Since steroid hor-
mones modulate renal sodium retention, it is likely that
variations in 11bHSD2 activity may be responsible for
the sensitivity of blood pressure to dietary salt. A salt-
sensitive response of blood pressure has not only been
observed in patients with hypertension, but has also been
well documented in young normotensive individuals [49].
These subjects also display a number of traits, including Fig. 3. Northern blot analysis of 11bHSD1 and 11bHSD2 gene expres-
suppression of the renin-angiotensin system, which can sion in human tissues. A commercial blot (Human Endocrine System
blot; Clontech Laboratories, Inc., Palo Alto, CA, USA) containing 2also be found in some patients with essential hyperten-
mg of poly A1 RNA per lane was used. b-Actin is shown as a controlsion [50]. It has therefore been suggested that salt-sensi- for loading and transfer of RNA.
tive individuals may be genetically predisposed to the
development of hypertension [51]. Our recent data sug-
gest that an impaired activity of 11bHSD2 is associated
with an increased susceptibility of blood pressure to salt creased levels of glucocorticoids to cross the placenta
and thus inhibit fetal growth. In humans, low birth weightload [52], an observation in line with the well-established
concept that low-renin hypertension is generally consid- is a risk factor for the development of hypertension in
adult life [56–59]. In fact, some clinical and experimentalered to be a salt-sensitive form of high blood pressure
[50]. These findings are in apparent contrast with the observations suggest that a decreased activity of placen-
tal 11bHSD2 reduces birth weight and produces hyper-observation of Litchfield et al [47], in which subjects
with the highest urinary free cortisol show the lowest tensive adult offspring [57–60]. Hence, a mild form of
11bHSD2 deficiency could also present with low birthsensitivity of blood pressure to dietary sodium. In this
study, only urinary free cortisol, but not cortisone or weight and late onset hypertension.
The 11bHSD2 enzyme has previously been shown to(THF 1 5aTHF)/THE, was measured [47], thereby not
allowing a direct evaluation of 11bHSD2 activity. More- be expressed at high levels in a few nonmineralocorticoid
target tissues [10]. In addition, we have recently shownover, a reduced 11bHSD2 activity correlates with a de-
crease in urinary excretion of free cortisone rather than that the human thyroid gland also expresses the message
at high levels (Fig. 3). However, immunostaining experi-an increased urinary free cortisol excretion [53]. Thus,
measuring cortisone and its metabolites or (THF 1 ments have been unable to demonstrate evidence of the
protein. It may be that translation of 11bHSD2 is tightly5aTHF)/THE in the urine seems to be the most appro-
priate assay of renal 11bHSD2 activity. controlled in this tissue or that the protein in the thyroid
is excessively unstable. Altered thyroxine levels have notOther observations on the metabolism of glucocorti-
coid hormones seem to link 11bHSD2 function with hy- been reported in AME patients; thus, the relevance of
thyroidal 11bHSD2 to hypertension remains to be estab-pertension. AME is associated with low birth weight
[14–16] and sometimes with stillbirth [54]. It seems likely lished. We also observed elevated levels of 11bHSD1
gene expression in the adrenal cortex and significantthat 11bHSD2 protects the fetus against the excessive
levels of maternal glucocorticoids [55, 56]. A deficient levels in the adrenal medulla (Fig. 3). Immunohistochemi-
cal studies have shown strong staining for 11bHSD1 infetal (placental) 11bHSD2 would therefore allow in-
Ferrari and Krozowski: 11bHSD2 and blood pressure 1379
the human adrenal cortex, without similar evidence in genetic association of a HSD11B2 flanking microsatellite
the medulla [61]. Collectively, these observations suggest and hypertension in African Americans with end-stage
that the 11bHSD enzymes are also involved in the pro- renal disease [67]. An association with a polymorphic
duction of glucocorticoids in the adrenal. It should be marker in exon 3 [Glu178/Glu (G534A)] of the HSD11B2
noted that there are many examples of differences in gene and end-stage renal disease was also recently de-
11bHSD1 and 11bHSD2 gene expression between spe- scribed; however, this marker was not associated with
cies. High levels of 11bHSD1 are present in the proximal essential hypertension in humans [68]. A mutation in the
tubule of the rat kidney, while the enzyme is absent in nucleotide, but not in the amino acid sequence, is not
the human kidney. Low levels of 11bHSD2 are expressed expected to affect 11bHSD2 activity. Thus, the signifi-
in the rat thyroid. High levels are present in sheep and rat cance of the association of end-stage renal disease with
adrenals, but only low levels are seen in human adrenal. this polymorphic marker is unclear. A newly identified
These evolutionary differences may reflect differences CA-repeat allele polymorphism was recently analyzed
in substrate utilization (corticosterone instead of corti- in a large series of families with essential hypertension,
sol) or kinetics of glucocorticoid binding, and demon- but no correlation was found between this marker and
strate the adoption of an important regulatory system blood pressure [69]. We analyzed the same polymorphic
by diverse populations of cells, many with no evidence marker in salt-sensitive subjects and found a positive
of mineralocorticoid activity. association between the homozygous A7 allele and a
Glycyrrhetinic acid, the active component of licorice, negative correlation with the heterozygous A7/A8 allele
is a potent inhibitor of 11bHSD [23]. Increased circulat- and salt sensitivity [52]. This suggests that the activity
ing levels of endogenous inhibitors of 11bHSD activity, of the 11bHSD2 enzyme may be genetically determined
termed “glycyrrhetinic acid-like factors” or GALFs, by variants in the HSD11B2-flanking regions or by the
have been hypothesized to inhibit 11bHSD2 activity and presence of undetected mutations in the HSD11B2 gene
therefore cause hypertension [62–65]. GALFs have been itself, an issue deserving further investigation. The ap-
detected in human urine and in increased amounts dur- parent divergent findings of these two studies may be
ing pregnancy [64]. The identity of these compounds has explained by the lack of selection for the blood pressure
not yet been determined. One potential candidate is 11b- response to salt load in the patients studied by Brand et
hydroxyprogesterone, which might be excreted in larger al [69].
amounts during pregnancy [66]. The physiological sig-
nificance of GALFs is also not yet established, although
CONCLUSIONSthe correlation of inhibitor levels with dietary sodium
intake in subjects with low-renin hypertension suggests There is evidence that an impaired 11bHSD2 activity
that increased GALF levels may be a consequence of may play a role in the pathogenesis of essential hyperten-
volume expansion, rather than a cause [63, 65]. sion in some patients and that this may be genetically
determined. Because 40% of patients with essential hy-
pertension have low renin levels, a number of these pa-GENETICS OF 11bHSD2 IN
tients may have a mild form of AME. Furthermore, asESSENTIAL HYPERTENSION
spironolactone causes ready remission, it is important toRecently, we and others reported on two sets of pa-
seek the diagnosis by genetic and clinical studies. Thetients with AME, each homozygous for a gene mutation
prevalence of mutations of HSD11B2 in the general pop-resulting in a minor deficiency in the 11bHSD2 enzy-
ulation of patients with essential hypertension is pres-matic activity [37, 38]. The only relevant findings in these
ently unknown. The epidemiology of such mutations issubjects were hypertension and suppressed plasma renin
relevant for two reasons: First, the prevalence is impor-levels, without other characteristic phenotypic features
tant in order to define the cost-benefit ratio for screeningthat could lead to the diagnosis of AME [37, 38]. These
patients with low-renin, low-aldosterone hypertension.cases indicate that a genetically determined decrease in
Second, the accurate diagnosis of AME should permit11bHSD2 activity can cause “essential hypertension.”
the design of more specific therapies for patients withThus, it is possible that a subset of patients among the
this disease.essential hypertensive population may actually suffer
from a very discrete form of AME. Several investigators
have sought an association between variants of the ACKNOWLEDGMENTS
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